

Department of Neurology, Stellar Chance Laboratories, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Introduction

Charcot-Marie-Tooth (CMT) Disease is a rare peripheral neuropathy that results in loss of motor or sensory functions in the hands, arms, legs, and feet of patients. CMT is hereditary with varying modes of inheritance, thus identifying the mutations causing disease can help inform future decisions. Additionally, depending on the genetic cause for the disease, there are available treatments, helping improve health outcomes for patients. In this study, three patients with CMT were analyzed and the associated mutations were investigated.





Methods

Initial Vetting of Patients by Dr. Steven Scherer based on specific characteristics

Blood Kits sent out to good candidates who are willing to participate

Once returned, blood samples sent out to partners of lab (GeneDX, Invitae, UMiami Genomics Lab) where a WES analysis of the samples is done

Samples analyzed using analysis software Genesis, with results examined based on segregation of disease, clinvar significance, mutation location, and rarity

Disease Causing Mutations in Patients with Charcot-Marie-Tooth Disease

Rohan Singh, Steven Scherer

Mitochondrial Inheritance in Patient 1



Patient 1 Variant Details in MT-ATP6 Gene

Gene 🗹 MT-ATP6

Variant type Missense

Chromosome position 🗹 ChrM:9185

MT-ATP6 gene is involved in oxidative phosphorylation in the mitochondria. Mutations in the MT-ATP6 gene can lead to reduced signal strength, causing the symptoms of peripheral neuropathy.

Patient 2 Variant Details in POLG Gene

Gene 🗹 POLG

Variant type Missense

Chromosome position 🗹 Chr15:89872271

POLG gene is involved in creating Pol γ which acts in the mitochondria. Similarly, mutations in the POLG gene can cause reduced signal strength which causes the symptoms of peripheral neuropathy.

Patient 3 Variant Details in POLG Gene

Gene 🗹 POLG

Variant type Missense

Chromosome position 🗹 Chr15:89866657

	Recessive Inheritance in Patient 3
h disease	PEN-86925-1002 PEN-86925-1001 PEN-86925-1003 PEN-86925-0101 PEN-86925-1001 PEN-86925-1003 PEN-86925-0101 PEN-86925-0101 PEN-86925-0102 PEN-86925-0101 PEN-86925-0102 PEN-86925-0101 PEN-86925-0102 PEN-86925-0101 PEN-86925-0102 PEN-86925-0101 PEN-86925-0102 PEN-86925-0101 PEN-86925-0102 PEN-86925-0102 PEN-86925-0102 PEN-86925-0102 PEN-86925-0102 PEN-86925-0102 PEN-86925-0102 PEN-86925-01

cDNA change 🗹 c.659T>C Protein change 🗹 Leu220Pro

cDNA change c.926G>A

Protein change 🗹 Arg309His

cDNA change 🗹 c.2243G>C Protein change 🗹 Trp748Ser



Conclusions

For Patient 1:

- Solved Mutation: MT-ATP6 (Leu220Pro)
- Mitochondrial Inheritance; Patient is Male so there is no risk to offspring

For Patient 2:

- Solved Mutation: POLG (Arg309His)
- Compound Heterozygous; Recessive; risk to offspring if mate is a carrier

For Patient 3:

- Solved Mutation: POLG (Trp748Ser)
- Autosomal Recessive; risk to offspring if mate is a carrier

Future Directions

- Analyze more patients and identify other causative mutations to expand the current database of patients
- Look into trends of these mutations across various patients
- Investigate potential biotechnological solutions that directly mitigate the symptoms caused by the mutation on a cellular level

Acknowledgements

I would like to acknowledge Dr. Steven Scherer and Dr. Stephan Zuchner, without whom this project would not have been possible.